Moderna Agrees $950M Patent Settlement, Removes Up to $2.25B Legal Overhang
Moderna agreed to pay $950 million in Q3 2026 to settle all Arbutus Biopharma and Genevant Sciences litigation, with up to $1.3 billion refundable if its appeal succeeds. The settlement removes patent overhang on mNEXSPIKE and mCOMBRIAX, underpins projected 2026 revenue growth and boosts liquidity to as much as $5.9 billion.
1. Global Settlement Terms
Moderna will pay $950 million in the third quarter of 2026 to fully resolve patent claims by Arbutus Biopharma and Genevant Sciences related to its COVID-era vaccines. The company will appeal a possible additional liability of up to $1.3 billion under Section 1498, with any refunded amounts paid with interest if the appeal succeeds.
2. Financial Impact and Liquidity Position
The $950 million charge will be recorded in Q1 2026, and Moderna projects end-2026 cash of $4.5 billion to $5 billion plus a $900 million credit facility, lifting total liquidity to as much as $5.9 billion. This settlement also eliminates uncertainty around royalty liabilities and supports anticipated funding for R&D and operations.
3. Pipeline and Strategic Outlook
By removing the legal overhang, Moderna can focus on advancing its infectious disease portfolio, including mNEXSPIKE and mCOMBRIAX. Management highlighted expectations for revenue growth in 2026 and progress toward breakeven by 2028 as key strategic milestones.
4. Analyst Insights
Analysts note that the total settlement range of $1 billion to $2.25 billion is lower than feared, lifting a major valuation overhang. Upcoming Phase 3 melanoma trial data is cited as a potential transformational catalyst for Moderna’s share price.